Company intelligence / Profile preview
ABX advanced biochemical compounds
Radeberg, Saxony, Germanyabx.de ↗
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
01
Overview
ABX has developed ¹⁷⁷Lu-PSMA-617 (sublicensed to Endocyte, now Novartis) and ¹⁸F-PSMA-1007 which is approved in selected European countries[1][5].
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalsPET tracersSPECT precursors
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Novartis (through Endocyte sublicense)pharmaceutical companies for R&D collaborations[1]
Beyond the preview
Go deeper on ABX advanced biochemical compounds.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABX advanced biochemical compounds.